Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Prurigo Nodularis, Hepatic Impairment
- Main trialPhase 2/3
- “To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Participants were randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, participants who received NAL ER were continued on NAL ER and participants who received placebo would then shift to NALER.”In the company’s words, NCT03497975 on ClinicalTrials.gov
- Other names
- NAL ER Tablets · NAL ER
Other drugs for Hepatic Impairment
- Custodiol-NDr. F. Köhler Chemie GmbH · Phase 3
- Rifaximin SSDBausch Health Americas, Inc. · Phase 3
- TYNADOTESinew Pharma Inc. · Phase 2
- LYG-LIV0001LyGenesis, Inc. · Phase 2
- NTZGenfit · Phase 2
- EGEN-5784eGenesis, INC · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Completed | 10 May 2022 | PRISM Study-Pruritus Relief Through Itch Scratch Modulation | |
| Phase 1Completed | 5 Feb 2020 | Study of Nalbuphine ER in Participants With Hepatic Impairment |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026